


Examining resistance to immunotherapy in ovarian cancer

December 15 2022



TME of HGSOC at single-cell resolution. **a**, Overview of the MSK SPECTRUM cohort and specimen collection workflow. **b**, UMAP plot of cells profiled by scRNA-seq colored by patient. Cell types are highlighted with gray outlines. **c**, Patient specificity for each cell type. Ov, ovarian. **d**, Number of cells identified per cell type next to a UMAP plot with cells colored by cell type. **e**, Number of cells profiled per tumor site next to a UMAP plot with cells colored by tumor site. UQ, upper quadrant. **f**, Site-specific enrichment of cell type composition in scRNA-seq, H&E and mpIF data fitted using a GLM. GLMs for H&E and mpIF

data were separated by tumor (T) and stroma (S) regions. The color gradient indicates the \log_2 -transformed odds ratio (red, enrichment; blue, depletion), and sizes indicate the Bonferroni-corrected $-\log_{10}(P \text{ value})$. **g**, Cell type composition based on scRNA-seq data for CD45⁻ and CD45⁺ samples. Upper panels, absolute and relative cell type numbers; lower panels, box plot distributions of sample ranks with respect to tumor site. **h**, Cell type composition based on H&E with lymphocyte ranks in tumor and stroma. Panels are analogous to those in **g**. **i**, Cell type composition based on mpIF with CD8⁺ T cell ranks in tumor and stroma. Panels are analogous to those in **g**. For **c** and **g–i**, violin plots and box plots are shown as the median, top and bottom quartiles; whiskers correspond to 1.5× interquartile range (IQR). **P*

Citation: Examining resistance to immunotherapy in ovarian cancer (2022, December 15) retrieved 26 February 2023 from <https://medicalxpress.com/news/2022-12-resistance-immunotherapy-ovarian-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.